Idexx Laboratories Q3 FY2026 results
$704.23+0.89%
Idexx Laboratories reported revenue of $1.21 billion, up 9.9% from a year earlier, net income of $317 million and diluted earnings per share of $4.01 against $3.40 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, filed 2 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $1.21B | $1.11B | +9.9% |
| Gross profit | $764.3M | $683.4M | +11.8% |
| Gross margin | 62.9% | 61.8% | +1.1 pts |
| Operating income | $402.3M | $354.8M | +13.4% |
| Operating margin | 33.1% | 32.1% | +1.0 pts |
| Net income | $317.1M | $274.6M | +15.5% |
| Diluted EPS | $4.01 | $3.40 | +17.9% |
| Operating cash flow | $449.7M | $402.3M | +11.8% |
| Capital expenditure | $28.93M | $31.11M | −7.0% |
| Free cash flow | $420.8M | $371.2M | +13.4% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Product revenue | $722.9M | up 10.2% |
| Service revenue | $491.4M | up 9.4% |
| IDEXX VetLab consumables revenue | $443.2M | up 14.3% |
| Reference laboratory diagnostic and consulting services revenue | $399.1M | up 10.0% |
| Rapid assay products revenue | $89.1M | up 0.6% |
| Recurring revenue | $77.5M | up 9.1% |
| CAG Diagnostics capital - instruments revenue | $51.5M | unchanged |
| CAG Diagnostics services and accessories revenue | $35.9M | up 5.3% |
| Systems and hardware revenue | $19.7M | up 17.0% |
| CAG revenue | $1.1B | up 10.2% |
| Water segment revenue | $58.8M | up 8.4% |
| LPD revenue | $34.8M | up 2.6% |
| United States revenue | $766.6M | up 8.7% |
| Europe, the Middle East and Africa revenue | $267.1M | up 9.0% |
| Asia Pacific revenue | $104.9M | up 15.6% |
| Canada revenue | $49.0M | up 18.5% |
| Latin America & Caribbean revenue | $26.6M | up 15.4% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $1.21B | +9.9% | $4.01 |
| Q2 FY2026 | 30 Jun 2026 | $1.22B | +9.7% | $4.27 |
| Q1 FY2026 | 31 Mar 2026 | $1.14B | +14.3% | $3.47 |
| Q4 FY2025 | 31 Dec 2025 | $1.09B | +14.3% | $3.08 |
| Q3 FY2025 | 30 Sep 2025 | $1.11B | +13.3% | $3.40 |
| Q2 FY2025 | 30 Jun 2025 | $1.11B | +10.6% | $3.63 |
| Q1 FY2025 | 31 Mar 2025 | $998.4M | +3.6% | $2.96 |
| Q4 FY2024 | 31 Dec 2024 | $954.3M | +5.8% | $2.62 |
More on Idexx Laboratories: financial statements · revenue · earnings per share
IDXX's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
